- Conditions
- Primary Sclerosing Cholangitis, Trisomy 7, Cholangiocarcinoma, Chemoprevention
- Interventions
- Erlotinib (Tarceva)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced May 21, 2026, 7:20 PM EDT